In this study, we found that cytoplasmic RAD51 expression was associated with MPR (higher percentage of viable tumor cells) and shorter OS time in patients with NSCLC receiving neoadjuvant chemotherapy. This evidence concerns the gene RAD51 and non-small cell lung carcinoma.